European Archives - Page 677 of 1176 - European Medical Journal

Physiological Comorbidity Care: The Unmet Need in Patients with Chronic Lung Diseases

PSYCHOLOGICAL distress significantly impacts patient quality of life (QoL), treatment adherence, mortality, and morbidity…

EMJ Podcast: A Conversation on Innovation

Jonathan and Mike Bewick explore incredible advancements in oncology and patient technology, the impact of Brexit on healthcare, and consider what doctors can learn from nurses.

EULAR Releases First Core Data for Rheumatology in Pregnancy

THE EUROPEAN League Against Rheumatism (EULAR) has collated and released its first consensus-based recommendations for prospective pregnancy registries…

Cytokine Storm Criteria Enable Early COVID-19 Diagnosis

CYTOKINE storm is the term given to immune responses triggered by escalated infections, such as in the coronavirus disease (COVID-19). Severe immune…

Joining forces with the NHS

With a focus on open channels of communication, pharma and the NHS have the potential not just to survive, but to truly thrive.

Q&A Webinar on the Management of Recurrent Cystitis

The aim of this webinar is to share highlights on the topic “Improving the management of recurrent cystitis in clinical practice: can we do more?”…

The road to representative trial recruitment

Achieving equal and accurate representation in clinical trials has long been a challenge for the pharmaceutical industry. We have made great progress towards the goal of patient inclusivity, but what more can be done to ensure that all patient groups are adequately represented and how can digital help to achieve this?

Pfizer's Mace Rothenberg on his passion for advancing oncology

Mace Rothenberg, Chief Medical Officer, Pfizer, speaks to us about his sustained passion for advancing the field of oncology, the importance of diverse representation in patient groups, and the challenges of balancing lifespan with health span.

Is pharma recession-proof?

How ‘recession-proof’ is pharma, and what challenges has COVID-19 posed to this famously robust industry?

The fight against the superbugs

How can the pharmaceutical industry and, in particular, medical affairs teams, take pragmatic approaches to combat and curb antimicrobial resistance?